Novo Nordisk said on Monday that in a late-stage trial, 40.4 per cent of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.
Open original sourceComments stay attached to this story.
Start a connected post from this article without changing the original story.
Israel launched a wave of airstrikes across southern Lebanon, killing 13 people, including women and children, Lebanon’s health minist…
Freeman Health System will hold its Breast Cancer Survivors Fair from 4-6 p.m. Thursday, Sept. 17, at the Women’s Center Conference Ro…
The annual event raises funds that the nonprofit Beyond Pink TEAM distributes to northeast Iowans receiving treatment for breast cance…
A sweeping new study shows why you should ditch plastic food wrapping whenever possible.
Health News: As FSSAI moves forward on defining thresholds for foods high in fat, sugar and/or salt (HFSS), and mandating prominent fr…
The Northwest Indiana Federation of Labor estimates union wages are 30% higher than average in Northwest Indiana, with 97% having heal…
Creators building their communities through the SpiderTaz Creator Program.
No comments yet.